Close Menu

NEW YORK (GenomeWeb) – Pacific Biosciences said after the close of the market on Monday that it plans to sell shares of its common stock in a public offering.

The Menlo Park, California-based maker of sequencing platforms did not disclose the number of shares it planned to sell or how much money it expects to raise. The offering is pursuant to a $150 million shelf offering declared effective in August 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.